Scientists to inject migraine patients with protein to spark aura attacks
NCT ID NCT07342296
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will give 21 people with migraine with aura an infusion of a protein called PACAP-38, or a placebo, to see if it can trigger an aura attack. The goal is to better understand what causes migraine aura, not to test a treatment. Participants will be monitored for 12 hours after the infusion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PACAP-38 (a protein given as an IV infusion)
- What this could lead to
- If it works, this could help researchers understand what causes migraine aura, potentially pointing toward new treatments.
- What could go wrong
- This is a very small, early study with only 21 people. It is designed to trigger symptoms, not to treat them, so there is no direct benefit to participants. Results may not apply to all migraine patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE AURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists aim to forecast migraine pain using wearable sensors and early symptoms
- New migraine sprays and tablets tested in ER for quick relief
- New digital program aims to ease migraine pain without drugs
- New migraine drug shows promise in Real-World study
- Heart procedure may offer lasting migraine relief, new study hopes to prove
- VR headsets take on migraine pain in new trial